Healthcare / Medical Instruments & SuppliesTaipei Exchange
$7.63
-0.37 (-4.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-7.9M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$458M
P/E
N/A
•EV/EBITDA
10.6x
↓ROE
-2.1%
↓Gross Margin
13.6%
↓Debt/Equity
0.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.6%
FCF CAGR
—
FCF margin
-1.0%
FCF / Net income
0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $753.5M · net income $-16.3M · FCF $-7.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $753.5M | $753.5M | $766.8M | $770.2M | $1.05B |
| Net Income | $-16.3M | $-16.3M | $29.1M | $-33.2M | $13.3M |
| EBITDA | $70.5M | $70.5M | $125.6M | $76.6M | $127.5M |
| EPS | — | — | 0.48 | -0.55 | 0.22 |
| Gross Margin | 13.6% | 13.6% | 18.5% | 10.1% | 13.3% |
| Operating Margin | -2.3% | -2.3% | 3.1% | -4.9% | 1.5% |
| Net Margin | -2.2% | -2.2% | 3.8% | -4.3% | 1.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.51 | 0.51 | 0.52 | 0.67 | 0.60 |
| Cash Flow | |||||
| Free Cash Flow | $-7.9M | $-7.9M | $10.0M | $-13.8M | $30.6M |
| Returns | |||||
| ROE | -2.1% | -2.1% | 3.7% | -4.5% | 1.7% |
| Valuation | |||||
| P/E | — | — | 21.46 | — | 84.32 |
| EV/EBITDA | 10.61 | 10.61 | 7.08 | 16.47 | 11.43 |
| P/B | 0.60 | 0.60 | 0.80 | 1.18 | 1.41 |
| Growth & Yield | |||||
| Revenue Growth | -1.7% | -1.7% | -0.4% | -26.9% | — |
| EPS Growth | — | — | 187.3% | -350.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.48 → n/d
Residual
-14.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.